Inozyme Pharma

18 articles with Inozyme Pharma

• 

  Clinical Catch-Up: January 4-8

  1/11/2021

  The new year began with a fairly low level of clinical trial news. Here’s a look.

• Inozyme Pharma Announces Authorization to Proceed in U.S. and U.K. with Phase 1/2 Clinical Trial of INZ-701 for the Treatment of ENPP1 Deficiency

  1/4/2021

  Program addressing rare mineralization disorders expected to enroll first subject in H1’21 and provide preliminary safety and biomarker data in H2’21

• 

  BioSpace Movers & Shakers, November 13

  11/13/2020

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• Inozyme Pharma Reports Third Quarter 2020 Financial Results and Provides Business Highlights

  11/12/2020

  Inozyme Pharma, Inc., a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue and skeleton, reported financial results for the third quarter ended September 30, 2020 and provided recent business highlights.

• Inozyme Pharma Appoints Kevin B. Johnson, Ph.D., MBA, as Senior Vice President, Regulatory Affairs

  11/9/2020

  Dr. Johnson Brings More Than 25 Years of Experience in Developing and Implementing Global Regulatory and Clinical Development Strategies from Preclinical Through Product Approval

• 

  BioSpace Movers & Shakers, Oct. 16

  10/16/2020

  Biopharma and life sciences companies bolster their leadership teams with these Movers & Shakers.

• Inozyme Pharma Appoints Yves Sabbagh, Ph.D., as Senior Vice President and Chief Scientific Officer

  10/13/2020

  Dr. Sabbagh Brings More Than 20 Years of Experience in Rare Genetic Disorders and Mineral Metabolism Research Development Programs

• Inozyme Pharma Reports Second Quarter 2020 Financial Results and Provides Business Highlights

  9/3/2020

  Upsized IPO in July 2020 raised $128.8 million in gross proceeds Submitted IND for INZ-701 for the treatment of ENPP1 deficiency; currently on FDA clinical hold pending completion of ongoing GLP toxicology studies Initiation of INZ-701 Phase 1/2 clinical trials anticipated in early 2021, as previously planned BOSTON, Sept. 03, 2020 (GLOBE NEWSWIRE) --   Inozyme Pharma, Inc. (Nasdaq: INZY), a rare disease biopharmaceutical company developing novel therapeutics for the treatment of di

• Inozyme Pharma Announces Closing of Initial Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares

  7/30/2020

  Inozyme Pharma, Inc. (“Inozyme”) (Nasdaq: INZY), a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization, today announced the closing of its initial public offering of 7,000,000 shares of common stock at a public offering price of $16.00 per share on July 28, 2020 and the closing of the sale of 1,050,000 additional shares of common stock on July 30, 2020 following the exercise in f

• Inozyme Pharma Announces Pricing of Initial Public Offering

  7/23/2020

  Inozyme Pharma, Inc. (“Inozyme”) (Nasdaq: INZY), a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization, today announced the pricing of its initial public offering of 7,000,000 shares of common stock at a public offering price of $16.00 per share, for gross proceeds of $112.0 million,

• Inozyme Pharma Announces Changes to Its Board of Directors

  6/16/2020

  Inozyme Pharma, Inc., a rare disease biopharmaceutical company developing novel therapeutics for the treatment of disorders of abnormal mineralization, announced today the appointment of Doug Treco, Ph.D., as Chairman of the Company’s Board of Directors

• Inozyme Pharma and GACI Global Initiate Patient Burden of Disease Study to Improve the Understanding of the Severity and Impact of Disease in Patients with ENPP1 Deficiency and ABCC6 Deficiency

  5/14/2020

  Inozyme Pharma, Inc. , a rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization impacting the vasculature, soft tissue and skeleton, and GACI Global ( www.gaciglobal.org ), a patient advocacy organization dedicated to bettering the lives of families affected by Generalized Arterial Calcification of Infancy and/or Autosomal Recessive Hypophosphatemic Rickets Type 2 (GACI/A

• Inozyme Pharma Expands Medical Leadership Team

  11/14/2019

  Strengthens Inozyme’s Ability to Advance Lead Candidate, INZ-701, into Clinical Trials

• Inozyme Pharma Raises $67 Million in Series A2 Financing to Develop Therapies for Rare Mineralization Disorders

  4/10/2019

  Financing to Advance Lead Development Program, INZ-701, through Clinical Proof of Concept in Two Indications

• Inozyme Pharma Receives Orphan Drug Designation for INZ-701 in the United States and European Union

  7/17/2018

  Novel Enzyme Replacement Therapy in Development for Treatment of ENPP1 Deficiency

• Inozyme Pharma Offers No-Cost Genetic Testing for Rare Calcification Disorders

  6/13/2018

  Inozyme Pharma (Inozyme), today introduced a no-cost, third-party genetic testing program designed to improve detection and understanding of two rare calcification disorders.

• Inozyme Pharma Appoints David Thompson, Ph.D., as Senior Vice President and Chief Scientific Officer

  5/1/2018

  Inozyme Pharma is a biopharmaceutical company dedicated to developing treatments for rare and debilitating metabolic diseases

• 

  Cambridge Startup Inozyme Nabs $49M and a Roster Packed With Seasoned Vets

  11/15/2017

  The $49M in Series A funding will be used to develop the company's enzyme replacement therapies for two rare diseases affecting infants and children and push the treatments into the clinic.